Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by JPkatzon Mar 26, 2019 8:31pm

131 Views

Post# 29539951

RE:RE:RE:RE:RE:RE:Likely Last Chance

You are trying to equate ate valuation to its book value??? lol Obviously you aren't very knowledgeable when it comes to biotech investing...there are many phase II companies valued in the hundreds of millions of dollars. This is undervalued as stands today, how about in six months when phase II is completed and they move towards phase III or a strategic exit? Remember 6 months before intial phase II results it went from .10c to .80c, 800% gain. Fastforward now here we are 6 months before results again... this time .25c being the low, how much will it rise this time?? That's why we are here buying shares right now, this has a very good chance of success which will yield a nice reward!!

Bullboard Posts

2024, a breakthrough year for silver